COGNIS® Cardiac Resynchronization Therapy Defibrillator (CRT-D)

The smallest, thinnest, high-energy CRT-D in the world

At 9.9 mm thin and only 32.5 cc, the COGNIS CRT-D is a full-featured device, offering improved safety design, enhanced diagnostics, and more flexible programming options compared to previous Boston Scientific devices— while providing excellent device longevity.

Compare COGNIS to the competition in size and longevity estimates

"John talks about his first reaction when he first laid eyes on COGNIS, the world's smallest, thinnest high-energy device."   Hear John's story >>

SmartDelay™ AV Optimization

• In the CRTAVO study, SmartDelay optimization for atrial sensing was 98% correlated to the accurate and reliable invasive pressure measurement LV dP/dtmax. For atrial pacing, the correlation was 96%¹
  
• Designed to recommend an optimal paced and sensed AV delays to maximize LV dP/dtmax based on an individual’s intrinsic conduction characteristics in 2.5 minutes or less
  
• Independently determines paced and sensed AV delays based on three inputs:
• Intrinsic conduction characteristics (sensed and paced AV intervals)
• Interventricular timing
• LV lead location

Atrial Arrhythmia Management

• Biventricular (BiV) Trigger helps deliver resynchronization therapy as prescribed.
  
• When used with VRR (Ventricular Rate Regulation), BiV Trigger can increase the percent of ventricular pacing during conducted atrial tachycardias and AF episodes.
  
• The LATITUDE system provides you with an optional Atrial Arrhythmia Burden alert that can be configured at a threshold that is right for your patient. An alert will be triggered if, within any rolling 24-hour window, the atrial arrhythmia burden exceeds that threshold since the last interrogation or LATITUDE weekly device check.

Enhanced Cardiac Resynchronization Therapy

• Works with a broad portfolio of LV leads designed to provide stability for a wide variety of venous anatomies
  
• Four LV lead fixation designs have an overall implant success rate of 97%.²
  
• Expanded Electronic Repositioning™ provides even more options to clinically manage CRT pacing post-implant, including six pacing vectors with a bipolar LV lead and two pacing vectors with a unipolar LV lead
  
• The LATITUDE Patient Management system gives you the ability to impact patient outcomes by monitoring for changes in the physician selected percent of cardiac resynchronization therapy pacing
  
• The CRT % pacing alert is designed to notify you that the cardiac resynchronization pacing percentage has dropped below a selected threshold.
  
• CustomSelect™ Architecture, a feature of LATITUDE, allows both device-following and health-following physicians to independently select follow-up and monitoring schedules that best meet the needs of their practice and their patients.

Assurance

• Designed, built, and tested through Aurora, Boston Scientific Cardiac Rhythm Management’s continuous quality improvement program
  
• Engineered for safety with rigorously tested self-correcting software and Safety Core™ redundant back-up hardware
  
• The LATITUDE system delivers confidence and assurance about device status through daily device checks.

^{*Based on number of patients reported at six quarters post launch.
1} CRTAVO data were prospectively collected. However, the data analyses were not prespecified. Refer to Appendix F in the COGNIS System Guide for clinical data on the hemodynamic performance of this feature.
² ACUITY™ Spiral U.S. clinical study. The ACUITY Spiral success rate with EASYTRAK^® family was 97.2%. Data on file.

C8-612